UPDATE: Trovagene Reported It Received A 'May Proceed' Notification From FDA For Phase 1b/2 Trial Of Ovansertib In Combo With Standard-Of-Care In Patients With mCRC Harboring KRAS Mutations
Benzinga Newsdesk